Claims

1. A tablet comprising:

(1*S*,2*S*,3*R*,5*S*)-3-[7-{[(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3*H*-[1,2,3]-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol; and

at least one disintegrating excipient;

wherein the tablet has a hardness of from about 50 to about 150N and a disintegration time of less than about 3 minutes.

2. The tablet according to Claim 1, wherein the tablet has a disintegration time of less than about 60 seconds.

3. The tablet according to Claim 1 or Claim 2, wherein the at least one disintegrating excipient comprises a fast oral disintegrating excipient.

4. The tablet according to any one of the preceding claims, wherein the at least one disintegrating excipient comprises at least one carbohydrate filler and at least one disintegrant.

5. The tablet according to any one of the preceding claims, wherein the at least one disintegrating excipient comprises mannitol.

6. The tablet according to any one of the preceding claims, wherein the at least one disintegrating excipient comprises crospovidone.

7. The tablet according to any one of the preceding claims, wherein the at least one disintegrating excipient comprises mannitol, xylitol, anhydrous dibasic calcium phosphate, crospovidone and microcrystalline cellulose.

8. The tablet according to any one of the preceding claims, wherein the at least one disintegrating excipient is a disintegrating excipient pre-mix that is present in an amount ranging from about 50% to about 80% by weight of the tablet.

9. The tablet according to any one of the preceding claims, wherein the (1*S*,2*S*,3*R*,5*S*)-3-[7-{[(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3*H*-[1,2,3]-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-

hydroxyethoxy)cyclopentane-1,2-diol is present in an amount of from about 10 to about 18% by weight.

10. The tablet according to any one of the preceding claims, wherein the tablet comprises about 60 mg or about 90 mg of (1*S*,2*S*,3*R*,5*S*)-3-[7-{[(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3*H*-[1,2,3]-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol.

11. The tablet according to Claim 10, wherein the tablet comprises about 90 mg of (1*S*,2*S*,3*R*,5*S*)-3-[7-{[(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3*H*-[1,2,3]-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol.

12. The tablet according to any one of the preceding claims, wherein the tablet has a hardness of from about 55 to about 90N.

13. The tablet according to any one of the preceding claims, wherein the tablet further comprises at least one anti-caking agent.

14. The tablet according to Claim 13, wherein the at least one anti-caking agent is present in an amount of from about 0.5 to about 1% by weight of the tablet.

15. The tablet according to any one of the preceding claims, wherein the tablet is obtainable by a process comprising wet granulation of:

(1*S*,2*S*,3*R*,5*S*)-3-[7-{[(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3*H*-[1,2,3]-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol; and

an anti-caking agent.

16. The tablet according to Claim 15, wherein the wet granulation process involves the wet granulation of a mixture comprising (1*S*,2*S*,3*R*,5*S*)-3-[7-{[(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3*H*-[1,2,3]-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol in an amount of at least about 35% of by weight of the dry ingredients in the mixture.

17. The tablet according to Claim 15 or Claim 16, wherein the wet granulation process involves the wet granulation of a mixture comprising (1*S*,2*S*,3*R*,5*S*)-3-[7-{[(1*R*,2*S*)-

2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3*H*-[1,2,3]-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol in an amount of up to about 70% by weight of the dry ingredients in the mixture.

18. The tablet according to any one of Claims 15 to 17, wherein the mixture used in the wet granulation process comprises said anti-caking agent in an amount ranging from about 0.1 to about 1% by weight of the dry ingredients in the mixture.

19. The tablet according to any one of Claims 15 to 18, wherein the product of the wet granulation process comprises granules having a D (v, 0.9) value of less than about 1600 µm.

20. The tablet according to any one of Claims 15 to 19, wherein, after completion of the wet granulation step, the product is mixed with a second amount of an anti-caking agent or a glidant.

21. The tablet according to Claim 20 wherein the second amount of an anti-caking agent or the glidant is present at from about 0.2 to about 0.6%, preferably from about 0.3 to about 0.6%, by weight of the tablet.

22. The tablet according to any one of Claims 15 to 21, wherein the tablet is obtainable by a process comprising wet granulation of:

(1*S*,2*S*,3*R*,5*S*)-3-[7-{[(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3*H*-[1,2,3]-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol;

an anti-caking agent; and

a binder.

23. The tablet according to Claim 22, wherein the binder is present in the wet granulation mixture at an amount ranging from about 2 to about 6%, preferably from about 3 to about 6%, by weight of the dry ingredients in the mixture.

24. The tablet according to any one of the preceding claims, wherein the tablet comprises one or more lubricants.

25. The tablet according to Claim 24, wherein the lubricant is present in an amount of from about 1 to about 2% by weight.

26. The tablet according to any one of the preceding claims, wherein the tablet comprises:

(1*S*,2*S*,3*R*,5*S*)-3-[7-{[(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3*H*-[1,2,3]-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol at from about 10 to about 18% by weight of the tablet;

hydroxypropyl cellulose at from about 0.9 to about 2% by weight of the tablet;

colloidal anhydrous silica at from about 0.5 to about 1% by weight of the tablet;

mannitol at from about 47 to about 67% by weight of the tablet;

xylitol at from about 2.5 to about 4% by weight of the tablet;

anhydrous dibasic calcium phosphate at from about 2 to about 3.5% by weight of the tablet;

microcrystalline cellulose at from about 9 to about 15% by weight of the tablet;

crospovidone at from about 5 to about 9% by weight of the tablet; and

sodium stearyl fumarate at from about 1 to about 2% by weight of the tablet.

27. The tablet according to any of the preceding claims, wherein the (1*S*,2*S*,3*R*,5*S*)-3-[7-{[(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3*H*-[1,2,3]-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol has a D (v, 0.9) particle size distribution of from about 5 µm to about 50 µm.

28. The tablet according to any of the preceding claims, wherein the (1*S*,2*S*,3*R*,5*S*)-3-[7-{[(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3*H*-[1,2,3]-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol is substantially present in the form of polymorph II.

29. The tablet according to any of Claims 1 to 27, wherein the (1*S*,2*S*,3*R*,5*S*)-3-[7-{[(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3*H*-[1,2,3]-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol is substantially present in the form of polymorph III.

30. A process for the preparation of a tablet as defined in any one of the preceding claims which comprises the step of mixing together (1*S*,2*S*,3*R*,5*S*)-3-[7-{[(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3*H*-[1,2,3]-triazolo[4,5-

d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol and at least one anti-caking agent along with, or in, a liquid, so providing a wet granulate.

31. The process according to Claim 30, wherein the wet granulate mixture is mixed with a high shear mixer.

32. The process according to Claim 30 or Claim 31, which further comprises:
(I) drying the wet granulate mixture,
(II) adding one or more excipients to the dried granulates, and then
(III) forming the mixture into tablets.

33. The process according to Claim 32, wherein the one or more excipients includes at least one disintegrating excipient as defined in any one of Claims 3 to 8, a second amount of an anti-caking agent as defined in Claim 20 or Claim 21, and/or a lubricant as defined in Claim 24 or Claim 25.

34. A blister pack comprising a blistered base sheet comprising one or more cavities, and a lidding sheet bonded to the base sheet, wherein the edge of the blister pack comprises at least one break in the blistered base sheet and the lidding sheet such that the blister pack is tearable at the break to expose the cavity.

35. The blister pack according to Claim 34, wherein the at least one break is positioned adjacent to one of the cavities.

36. The blister pack according to Claim 34 or Claim 35, wherein the break separates two regions of the edge of the blister pack which are capable of being gripped and pulled apart to tear the blistered base sheet and the lidding sheet.

37. The blister pack according to any one of Claims 34 to 36, wherein the break is a cleft or an incision.

38. The blister pack according to any one of Claims 34 to 37, wherein the innermost part of the break is at least 3 mm from the nearest cavity.

39. The blister pack according to any one of Claims 34 to 38, wherein the blister pack comprises at least one break positioned adjacent to each cavity.

40. The blister pack according to any one of Claims 34 to 39, wherein the blistered base sheet comprises an aluminium layer or a polymer layer.

41. The blister pack according to Claim 40, wherein the blistered base sheet has a thickness of about 100 µm to about 200 µm.

42. The blister pack according to any one of Claims 34 to 41, wherein the lidding sheet comprises an aluminium layer.

43. The blister pack according to Claim 42, wherein the lidding sheet has a thickness of about 15 µm to about 60 µm.

44. The blister pack according to any one of Claims 34 to 43, wherein the blister pack comprises at least two cavities and further comprises a perforated region which forms a tear path passing between two of said cavities.

45. The blister pack according to any one of Claims 34 to 44 wherein the blister pack contains one or more tablets as defined in any one of Claims 1 to 29.

46. Use of a composition comprising:

(1*S*,2*S*,3*R*,5*S*)-3-[7-{[(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3*H*-[1,2,3]-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol; and

at least one disintegrating excipient;

in the manufacture of a medicament for use in treating or preventing atherothrombotic events in patients with cardiovascular disease, wherein the medicament is in the form of a tablet as defined in any one of Claims 1 to 29.

47. The use according to Claim 46, wherein the atherothrombotic events are selected from the group consisting of cardiovascular death, myocardial infarction, stroke and peripheral arterial disease.

48. Use of a composition comprising:

(1*S*,2*S*,3*R*,5*S*)-3-[7-{[(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3*H*-[1,2,3]-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol; and

at least one disintegrating excipient;

in the manufacture of a medicament for use in treating or preventing stent thrombosis, wherein the medicament is in the form of a tablet as defined in any one of Claims 1 to 29.

49. The use according to any one of Claims 46 to 48, wherein said medicament is to be administered to an elderly patient.

50. The use according to any one of Claims 46 to 49, wherein said medicament is to be administered to a patient that has suffered a myocardial infarction or a stroke.